GW succumbs to a Jazz overture
A focus on rare diseases and regulatory acceptance of cannabis make GW the subject of a $7.2bn buyout.
Atlantis sinks for Pharmamar and Jazz
Pharmamar’s pivotal small cell lung cancer trial is finally confirmed a dud, but will the FDA pull Zepzelca from the market?
Key biotech catalysts approach
Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
Go or no go? Pandemic looms over FDA timelines
Approval decisions are due for Jazz, Gilead and Galapagos in July, while Glaxo is preparing for a panel.
Important catalysts approach for smaller biotechs
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.
